|
Mon, 04/14/2025 - 09:53 |
Inhibikase Therapeutics Announces Appointment of David McIntyre as Chief Financial Officer |
|
Thu, 03/27/2025 - 20:57 |
Inhibikase Therapeutics Announces 2024 Financial Results and Highlights Recent Activity |
|
Tue, 02/18/2025 - 13:57 |
Inhibikase Appoints Industry Veteran Mark Iwicki as CEO to Drive Next Stage of Companys Growth |
|
Mon, 06/17/2024 - 12:04 |
Inhibikase Therapeutics Completes Enrollment of the Phase 2 201 Trial Evaluating Risvodetinib in Untreated Parkinsons Disease |
|
Wed, 06/05/2024 - 11:22 |
Inhibikase Therapeutics Announces Expansion to its Therapeutic Pipeline and Updates its Research and Development Programs |
|
Tue, 05/21/2024 - 06:17 |
Inhibikase Therapeutics Announces Pricing of Registered Direct Offering and Warrant Inducement, Priced At-The-Market for Aggregate Gross Proceeds of $4.0 Million |
|
Wed, 05/15/2024 - 11:13 |
Inhibikase Therapeutics Announces Request for Withdrawal of S-1 Registration Statement |
|
Fri, 05/10/2024 - 04:58 |
Inhibikase Therapeutics Announces Final Pre-IND Meeting Outcomes for IkT-001Pro as a Treatment for Pulmonary Arterial Hypertension |
|
Thu, 02/29/2024 - 03:52 |
Inhibikase Therapeutics Announces Full Outcomes of its Pre-NDA Meeting with the FDA for IkT-001Pro |
|
Wed, 02/07/2024 - 17:48 |
Inhibikase Therapeutics Announces Preliminary Outcomes of its Pre-NDA Meeting with the FDA on the Pathway for Approval for IkT-001Pro in Blood and Gastrointestinal Cancers |
|
Thu, 02/01/2024 - 13:32 |
Inhibikase Therapeutics Announces Publication Highlighting Results from its Phase 1 Studies with Risvodetinib |
|
Fri, 01/19/2024 - 13:52 |
Inhibikase Therapeutics Announces Planned Retirement of Chief Financial Officer Joseph Frattaroli |
|
Mon, 12/12/2022 - 12:59 |
Inhibikase Therapeutics Announces Dosing of First Subjects in its '501' Bioequivalence Study of IkT-001Pro |
|
Tue, 11/22/2022 - 08:57 |
Inhibikase Therapeutics to Present at Piper Sandler 34th Annual Healthcare Conference |
|
Fri, 08/26/2022 - 16:15 |
Inhibikase Therapeutics Announces FDA Clearance of Investigational New Drug Application for IkT-001Pro for the Treatment of Chronic Myelogenous Leukemia |
|
Tue, 08/23/2022 - 06:01 |
Inhibikase Therapeutics Announces Dosing of First Patient in its Phase 2a '201' Clinical Trial of IkT-148009 to Treat Parkinson's Disease |
|
Mon, 06/13/2022 - 05:10 |
Inhibikase Therapeutics Announces Advancement of IkT-148009 Phase 2 '201' Program Following FDA Review |
|
Thu, 04/21/2022 - 16:28 |
Inhibikase Therapeutics to Participate at the B. Riley Securities' 2022 Virtual Neuro & Ophthalmology Conference |
|
Wed, 04/06/2022 - 01:18 |
Inhibikase Therapeutics to Host Virtual KOL Investor Event on April 20, 2022 |
|
Thu, 03/31/2022 - 02:40 |
Inhibikase Therapeutics Reports Full Year 2021 Financial Results and Highlights Recent Period Activity |
|
Fri, 03/25/2022 - 11:23 |
Inhibikase Therapeutics to Report Full Year 2021 Financial Results on March 31, 2022 |
|
Wed, 03/23/2022 - 07:45 |
Inhibikase Therapeutics to Participate in the Maxim Group 2022 Virtual Growth Conference |
|
Tue, 03/08/2022 - 09:38 |
Inhibikase Therapeutics to Present Phase 1/1b Clinical Data at the Upcoming AD/PD Alzheimer's & Parkinson's Diseases Conference |
|
Wed, 01/05/2022 - 06:23 |
Inhibikase Therapeutics Highlights 2022 Pipeline Goals and Milestones |
|
Mon, 11/29/2021 - 03:54 |
Inhibikase Therapeutics Announces Publication Highlighting Mechanism of Disease and the Potential of Oral c-Abl Kinase Inhibitor Therapy for the Treatment of Parkinson's Disease |
|
Wed, 10/27/2021 - 15:16 |
Inhibikase Therapeutics to Participate in Upcoming Michael J. Fox Foundation Alpha-Synuclein Summit |
|
Mon, 10/18/2021 - 23:44 |
Inhibikase Therapeutics Announces Dosing of First Parkinson's Patient in its Phase 1b Clinical Trial of IkT-148009 |
|
Mon, 10/04/2021 - 08:49 |
Inhibikase Therapeutics Announces Interim Three-month Results from Chronic Toxicology Studies of its Oral c-Abl Kinase Inhibitor, IkT-148009, in Development for Treatment of Parkinson's Disease |
|
Mon, 09/06/2021 - 20:46 |
Inhibikase Therapeutics to Present at Upcoming H.C. Wainwright 23rd Annual Global Investment Conference |
|
Mon, 07/26/2021 - 14:58 |
Inhibikase Therapeutics Receives FDA Clearance To Begin Evaluation of IkT-148009 in Parkinson's Patients |
|
Fri, 06/18/2021 - 16:39 |
Inhibikase Therapeutics Announces Closing of Follow-On Offering of Common Stock |
|
Tue, 06/15/2021 - 13:58 |
Inhibikase Therapeutics Prices Follow-On Public Offering of Common Stock |
|
Tue, 05/25/2021 - 15:52 |
Inhibikase Therapeutics to Present at Upcoming Jefferies Virtual Healthcare Conference & Others |
|
Wed, 04/21/2021 - 11:15 |
Inhibikase Therapeutics to Present at Sachs 4th Annual Neuroscience Innovation Forum |
|
Mon, 01/04/2021 - 09:54 |
Inhibikase Therapeutics Announces Partnership with Clintrex Research Corporation; C. Warren Olanow, MD, to Serve as Interim Chief Medical Officer |
|
Sun, 12/27/2020 - 20:38 |
Inhibikase Therapeutics Announces Closing of Initial Public Offering |
|
Mon, 12/21/2020 - 22:33 |
Inhibikase Therapeutics, Inc. Announces Pricing of its Initial Public Offering |
|
Thu, 12/03/2020 - 00:08 |
Inhibikase Advances Development Program for Multiple System Atrophy (MSA) Based on Demonstration of Key Role of c-Abl Kinase in MSA Neurodegeneration |
|
Mon, 07/27/2020 - 15:41 |
Inhibikase Files Registration Statement for Proposed Initial Public Offering |
|
Tue, 04/09/2019 - 13:00 |
Inhibikase Therapeutics Announces Appointment of Elizabeth OFarrell to its Board of Directors |
|
Tue, 03/19/2019 - 12:03 |
Inhibikase Therapeutics Expands its Scientific Advisory Board with the Appointment of Leading Experts in Parkinsons Disease |
|
Tue, 03/05/2019 - 12:55 |
Inhibikase Therapeutics Appoints Leading Experts in Parkinsons Disease to its Scientific Advisory Board |
|
Tue, 02/26/2019 - 14:23 |
Inhibikase Therapeutics Files Two Investigational New Drug Applications for IkT-148009, a Disease-Modifying Therapy for Parkinsons Disease |
|
Sun, 01/06/2019 - 07:17 |
Inhibikase Therapeutics, Inc. Appoints Marty Joyce as Chief Financial Officer |
|
Tue, 05/28/2013 - 06:31 |
Inhibikase Therapeutics to Present at Industry Conference on Drug-Induced Progressive Multifocal Leukoencephalopathy |
